| Random assignment
Patients have been randomly selected to a standard (STAND) BP target (50th to 95th percentile of 24-hour MAP) or an intensified (INTENS) BP target (<50th percentile of 24-hour MAP). 10 Throughout the 3-year study, BP was measured in the renal clinic using oscillometric BP monitor (Omron M6, Omron Healthcare), eGFR according to Schwartz formula, and proteinuria (protein/creatinine ratio) were tested every month, and ABPM was carried out every 6 months. Treatment of BP was managed according to 24-hour MAP levels. Any antihypertensive agent approved for children 11 was allowed to be added to the patient's antihypertensive therapy. A standardized BP protocol was proposed (in case of proteinuria presence: first-line ramipril, second-line amlodipin, third-line diuretic, fourth-line beta-blocker; in case of negative proteinuria: first-line amlodipin, second-line ramipril) but was not compulsory. Ramipril or any ACE was not compulsory in any patient. Antihypertensive score modified according to Guidi et al 12 was calculated in each patient at every outpatient visit (briefly:
1 antihypertensive drug =1 point, 2 antihypertensive drugs =2
points, maximal dose of antihypertensive drug(s) =1 additional point(s)). The mean antihypertensive score was 2.1 ± 1.7 points in INTENS and 2.2 ± 1.9 points in the STAND group.
| Ambulatory 24-hour BP monitoring
Ambulatory BP monitoring was performed using SpaceLabs 90217 oscillometric device (SpaceLabs Medical, Redmont, WA). A cuff was selected according to the patient's arm circumference and given on the non-dominant arm. 13 The monitors measured BP every 20 minutes during daytime and every 30 minutes during nighttime. The data were analyzed by using an individual diary. Mean systolic and diastolic BP at daytime, nighttime, and 24 hour were calculated and compared with the reference values from healthy children. 10 The MAP SDS was calculated according to the body height and sex of the patient. 
| Outcome measures
The primary endpoint was the annual reduction in eGFR (mL/ min/1.73 m 2 /y). Secondary endpoints were changes in 24-hour MAP, proteinuria, graft and patient survival, and safety.
| Laboratory assessments
Serum and urinary creatinine concentrations were measured at the local laboratory using the enzymatic method (automatic analyzer Advia 1800, Siemens) and urine protein concentration by turbidimetry method. The eGFR was estimated by means of the new bedside Schwartz formula from 2009, 9 and proteinuria was expressed as protein/creatinine ratio (mg/mmol creatinine, reference range <22).
| Statistical analysis
Primary outcome was analyzed primarily according to the intension-to-treat protocol and secondarily according to the per-protocol principle. Longitudinal changes in eGFR, BP, and proteinuria were evaluated with the use of one-sided t test. Results are expressed as mean ± SD in normally distributed data or median and range in non-normally distributed data. The power analysis could not be performed as no study yet investigated the effects of strict BP control <50th percentile in pediatric or adult patients after KTx.
| RE SULTS

| Patients
A total of 23 of the 32 patients who entered the screening period met the inclusion criteria (baseline characteristics in Table 1 ) and were randomized either to intensified (INTENS) BP control group (n = 12) or to standard (STAND) BP group (n = 11). The two treatment groups were not different with respect to baseline characteristics ( Table 1 ). The primary renal diseases were nephronophthisis (n = 3), idiopathic steroid resistant nephrotic syndrome (n = 3), autosomal recessive polycystic kidney disease (n = 3), obstructive uropathy together with posterior urethral valve (n = 5), branchio-oto-renal syndrome (n = 2), renal cysts and diabetes syndrome-HNF1B-beta nephropathy (n = 2), genetic form of steroid resistant nephrotic syndrome (n = 2, mutation in NPHS2 and WT1 gene), reflux nephropathy (n = 1), chronic tubulointerstitial nephritis (n = 1), and congenital renal hypoplasia (n = 1).
Two patients had to be withdrawn from the trial during the course of the 3-year study period; the reasons for withdrawal were steroid-resistant acute rejection and antibody-mediated rejection (one child in each group). The remaining 21 were included in the analysis of the primary and secondary endpoints.
| Primary endpoint
A total of 11 of 12 patients (92%) in the INTENS group and 10 of 11 patients (91%) in the STAND group completed the 3-year study. The results of eGFR during the whole study period are given in Table 2 and Figure 1 .
The annual reduction in eGFR did not differ significantly be- 
| Secondary endpoints
The 3-year graft and patient survival in each group was 100%. There was no significant change in proteinuria in any group after 3 years of the study or between the groups (Table 2) .
No child experienced hypotension, acute drop of graft function, hyperkalemia, or any other serious adverse event during the 3 years of the trial.
| D ISCUSS I ON
The results of this 3-year interventional randomized controlled ESCORT trial have shown that intensified control of BP, on contrary to the results from the ESCAPE study on children with chronic native kidney disease, could not delay the progression of chronic allograft dysfunction in pediatric patients after KTx.
Arterial hypertension is one of the most important non-immunological predictors for allograft failure. 14 This has been shown, for example, in the Collaborative Transplant Study. 3 This study demonstrated that there is a negative association between BP and graft survival. The association between BP and graft survival has been then demonstrated by many other trials in adults and children.
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It is therefore clear that elevated BP is clearly associated with worse graft survival in comparison with normal BP. The association between BP and graft survival is seen also in the range of normal BP; however, it is not known whether the linear association goes also down to the subnormal levels (<50th percentile). In our previous prospective interventional study on BP control, we could demonstrate that pediatric patients remaining hypertensive during this prospective 2-year interventional trial lost significant graft function in comparison with patients in whom BP was decreased to normotension. for adults 20 but there is no evidence from randomized studies showing that this target BP which is lower than the standard target BP for general population (<140/90) will result in better allograft survival.
Moreover, the KDOQI US commentary states the NKF recommen-
dation is not based on any scientific evidence and clinical relevance and that no randomized controlled trial has ever been carried out to test the hypothesis if the BP level achieved throughout the course of study would positively impact allograft function or survival and they made a research recommendation that there is a great need for prospective randomized controlled trial in patients after KTx. 21 The same is true also for pediatric transplanted patients.
There is also no consensus which drug(s) should be the first-line drug(s) in patients after KTx. In adults, a 2-year double-blind randomized controlled trial has demonstrated that calcium channel blocker (CCB) nifedipine improved graft function compared to ACEI lisinopril. 22 But it is still controversial if the increased GFR induced by the calcium channel blocker will have negative effects on longterm graft survival due to the elevated intraglomerular pressure and filtration caused by the CCBs predominant afferent arteriolar vasodilation. This question in still unanswered because no long-term prospective interventional controlled studies have been yet performed.
ACEIs are the first-line antihypertensive drugs in hypertensive patients with chronic native kidney diseases due to their antiproteinuric and renoprotective properties. 23, 24 However, no such additional positive effect in KTx recipients has been observed in the Collaborative Transplant Study. 25 Therefore, we did not use ACEI as a standard protocol treatment in all our patients in contrary to the ESCAPE trial.
Despite the highly significant decrease in 24-hour BP, there was no benefit of strict BP reduction on the annual decline of graft function. Therefore, it seems that on contrary to children with native chronic kidney nephropathies in ESCAPE trial, decrease in BP below the pediatric population mean is not associated with decrease in progression of chronic allograft dysfunction. One of the possible speculative explanation could be the numerical (but not statistical significant) higher use of ACEI in the intensified group of patients (82% vs 40%) as in the double-blind randomized trial on adult patients the patients who used ACEI that decreases GFR due to predominant efferent arteriolar vasodilation had lower graft function that those being on nifedipin that increases GFR due to predominant afferent arteriolar vasodilation. 22 Another speculative reason could be the numerical (but again not statistical significant) decline of GFR in the first year in the intensified group in comparison with slightly increased in the standard group (Figure 3 ) that could be due to much higher decrease in BP in the first year in the intensified group (lowering BP reduces renal perfusion pressure and often also GFR) or (not significantly) higher use of ACEIs that can cause acute drop of GFR. On the contrary, in the second and third year, the decline in GFR was numerically lower in the intensified group.
Our result is different from the results of most retrospective studies which have shown that normal BP has a beneficial effect on renal function compared to high BP. 26 The possible explanations for such difference could be better BP control in the standard control group as speculated also by Cameron et al. 27 In their observational cohort study, they did not find, similar to our study, any difference in the GFR decline between hypertensive and normotensive children.
The annual reduction in GFR was remarkable similar to our study Therefore, we can speculate that renal transplant recipients do not need systolic BP <120 mm Hg which corresponds in most children with a BP <50th percentile. Another reason for negative result of our trial can be better pharmacological control of proteinuria by ACEIs or ARBs, and proteinuria was present in only 14% of patients at the end of the study which is much lower prevalence than in observational studies (40%-80%). 6 It is well known that antihypertensive therapy is much more effective in proteinuric than in non-proteinuric nephropathies. 8 We could not find any difference in proteinuria between both treatment groups. The reason for the fact that intensified BP control did not result in lower proteinuria could be that the use of dihydropyridine calcium channel blockers in our study that tend to increase proteinuria might have compromised the ability of lower BP to reduce proteinuria.
There is no similar study in the literature investigating different BP targets for preventing chronic allograft dysfunction in pediatric or even in adult patients. Therefore, our study is the first ever study conducted to investigate which BP target is better in pediatric or adult patients after KTx.
Our study has several limitations, mainly the small number of included patients that can hamper the statistical power of the trial.
This very small sample size is the major limitation of our study.
Unfortunately, we could not include all children from our centre because of the age limit and multicentre study was not possible due to financial reasons. A larger study with higher number of patients would improve the statistical power of the results. We have also included only one population (Caucasian), and therefore, our results might not be true in other populations. The duration of the study was 3 years which is two years shorter that the ESCAPE trial; however, we think that additional two years would not change the negative results of the trial. Further limitation of our study design is the observation that in the standard group, some patients had MAP down to the 50th percentile and therefore not sufficient different from children in the intensive group with MAP below the 50th percentile. Greater separation between the two groups, for example, a lower bound of the 75th percentile in the standard group compared to below the 50th percentile in the intensive group, might have been more informative.
The main strength of our trial is that it is the first ever study on pediatric or even in adult patients after KTx that investigated whether lower BP target would lead to slower progression of chronic allograft dysfunction. The other strengths are the ABPM-guided antihypertensive treatment protocol, uniform conditions for all participating patients (single center).
In conclusion, targeting ambulatory BP to the subnormal level (<50th percentile) is not associated with slowing the progression of chronic allograft dysfunction or proteinuria in children after KTx;
however, the result needs to be interpreted keeping the major limitation in mind. 
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